exa-cel
Vertex pharmaceuticals,CRISPR therapeutics AG
[]
impressive data at #eha22 for and ' gene-editing drug exa-cel for beta thalassaemia and sickle cell disease bode well for regulatory filings due later this year 
https://t.co/O0ZJQGMjEP, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate